Loading
NBTXR3 is Nanobiotix's radioenhancer: a single injection of hafnium oxide nanoparticles that makes ordinary radiotherapy hit harder inside the tumour. It carries a European CE mark for soft-tissue sarcoma and is in a phase 3 trial in head and neck cancer with Johnson and Johnson.
NBTXR3 was developed by Nanobiotix in Paris. In the Act.In.Sarc phase 2/3 trial, adding the nanoparticles to preoperative radiotherapy for locally advanced soft-tissue sarcoma doubled the rate of pathological complete response, and the product received a CE mark (as Hensify) in 2019. The NANORAY-312 phase 3 trial tests it with radiotherapy, with or without cetuximab, in elderly patients with head and neck cancer who cannot have cisplatin, under a 2023 licence to Johnson and Johnson; trials with immunotherapy in lung and other cancers continue.
Crystalline hafnium oxide nanoparticles injected once into the tumour absorb X-rays far more strongly than tissue and release showers of electrons, multiplying the energy deposited inside the tumour without changing the dose to surrounding organs.
1.NBTXR3 (hafnium oxide nanoparticles) slips into a pocket on its target.
| Region | Year | Indication |
|---|---|---|
| EU | 2019 | CE mark: locally advanced soft-tissue sarcoma of the limb or trunk wall, with preoperative radiotherapy |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"NBTXR3" OR ABSTRACT:"NBTXR3" OR TITLE:"hafnium oxide nanoparticles" OR ABSTRACT:"hafnium oxide nanoparticles" OR TITLE:"Hensify" OR ABSTRACT:"Hensify" OR TITLE:"JNJ-90301900" OR ABSTRACT:"JNJ-90301900") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NBTXR3 (hafnium oxide nanoparticles), not a curated reading list.
Shares Radiosensitisers, Head and neck squamous cell carcinoma and the tag radiation-wave3.
Shares Sarcomas (soft tissue, bone, GIST) and the tag radiation-wave3.
Shares Head and neck squamous cell carcinoma and the tag radiation-wave3.
Shares Head and neck squamous cell carcinoma and the tag radiation-wave3.
Shares Act.In.Sarc, NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial, Sarcomas (soft tissue, bone, GIST).
Shares Radiosensitisers, Head and neck squamous cell carcinoma, IMRT / IGRT (modern external beam).
Shares Radiosensitisers, Head and neck squamous cell carcinoma, IMRT / IGRT (modern external beam).